STREAM (Evaluation of a Standardised Treatment Regimen of Anti-tuberculosis Drugs for Patients with Multidrug-resistant Tuberculosis) treatment regimens.

Slides:

Advertisements

Similar presentations

The TB Alliance-Bayer Moxifloxacin Deal

Advertisements

Management of Drug-Resistant Tuberculosis Your name Institution/organization Meeting Date International Standard 12.

New approaches in TB diagnosis and treatment Prof. M.A. Tageldin.

Second-line Anti-TB drugs

New drugs and regimens for TB: 2015 update

1 Constructing a regimen Session 5. USAID TB CARE II PROJECT Principles of designing an MDR-TB treatment regimen Include at least four second-line anti-TB.

XDR-TB and management options Ninth Technical Advisory Group and National TB Programme Managers Meeting TB Control in the Western Pacific Region, Manila,

Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.

TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated million persons.

Bedaquiline: Practical use and interim results in France Dr Mathilde Jachym 17 th of February Yerevan New treatments and approaches.

Christoph Lange & Giovanni Sotgiu Principles of designing a TB and MDR-TB drug regimen.

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc. Chapter 89 Antimycobacterial Agents: Drugs for Tuberculosis, Leprosy,

Introduction to the Forms Julie Tomaro, BSN Washington State Department of Health INTERJURISDICTIONAL TB NOTIFICATION (IJN) TRANSFER AND FOLLOW-UP FORMS.

Anri Uys (MSc Pharmacology, BPharm NWU) Medicines Information Centre, Division of Clinical Pharmacology University of Cape Town.

TB 101 Part II Brenda Mayes, R. N. March TREATMENT TB DISEASE MDR XDR LATENT TB INFECTION.

Treatment of Tuberculosis: New Case Case Studies Module 7A2 – March 2010.

By Luke Carroll 1B.   Tuberculosis (TB) is an infectious disease that usually infects the lungs, but can attack almost any part of the body. What Is.

Infectious Conditions of the Lower Respiratory Tract.

Acquired Drug Resistance  64 year old female of Hmong ethnicity with long standing, poorly controlled diabetes. No hx TB dx/tx.  11/6/08 CXR “active.

By: Mpho Kontle and Topo Moses. Introduction & Etiology Multi-drug-resistant tuberculosis (MDR-TB) is defined as tuberculosis that is resistant to at.

PanACEA Studies: Phase I Phase IIa Phase IIb Phase III Q203 BTZ043

Treatment Regimens for Pulmonary Tuberculosis Caused by Drug- Susceptible Organisms Initial PhaseContinuation Phase RegimenDrugs Interval and Doses (Minimal.

Global Tuberculosis Control 2007 Did we reach the 2005 targets? Will we achieve the Millennium Development Goals?

Ward 5D Linda Iskandar 1. Patient MR From Nepal, has been in Australia for 2 years on a dependent student visa studying nursing. Presenting complaints.

Novel Regimen Options for DR-TB Treatment

Evaluation of a Standardized Treatment Regimen of Anti-Tuberculosis Drugs for Patients with MDR-TB (ST REAM) Nehemiah Nhando UZ-UCSF ANNUAL RESEARCH DAY.

Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis N Engl J Med 2008;359: R2 이 설 라.

Drug Resistant Tuberculosis

Treatment for Multi-drug Resistant TB

STREAM Trials Andrew Nunn MRC Clinical Trials Unit at UCL

STAND Trial NC-006 (M-Pa-Z) Dr Suzanne Staples Principal Investigator at THINK 26 Mar 2015.

Treatment of TB Disease

Treatment algorithm for tuberculosis

CHM 708 Anti-Bacterial Drugs.

2. Active TB drug-safety monitoring : rationale and mechanisms in the context of TB & MDR-TB treatment Multi-partner training package on active TB drug.

MDR-TB Update Dr Kelvin Charambira

Treatment algorithm for tuberculosis

1 Drug susceptible TB Limited resistance MDR-TB (Frieden, 1993) XDR-TB

Dr Dawood Quiz questions.

Rapid diagnosis of pyrazinamide-resistant multidrug-resistant tuberculosis using a molecular-based diagnostic algorithm S.O. Simons, T. van der Laan,

A) IS6110 restriction fragment length polymorphism (RFLP) and b) spoligotyping patterns of a multidrug-resistant tuberculosis (MDR-TB) cluster. a) IS6110.

Description of the design of three recent phase III clinical trials incorporating fluoroquinolone antibiotics in treatment-shortening regimens for pulmonary.

Characterization of Mycobacterium tuberculosis isolated from cancer patients with suspected tuberculosis infection in Egypt: identification, prevalence,

Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.

L. Zhang, Q. Meng, S. Chen, M. Zhang, B. Chen, B. Wu, G. Yan, X

Timeline of development of key elements of the Cambodian MDR-TB treatment programme. *GLC1 application for patients enrolled in the CAMbodian Early vs.

Clinical Epidemiology and Global Health

Percentage of previously treated tuberculosis (TB) cases with multidrug-resistant (MDR)-TB. Percentage of previously treated tuberculosis (TB) cases with.

Kaplan–Meier analysis of survival over 2 years of treatment with riociguat in the CHEST-2 study [54]. Kaplan–Meier analysis of survival over 2 years of.

Smoking cessation rate as point prevalence quit rate from year 1 to 5 in the Lung Health Study with 5,587 chronic obstructive pulmonary disease patients.

Tuberculosis drug-resistance in Lisbon, Portugal: a 6-year overview

CASE HOLDING FOR PMDT.

Profile of Pseudomonas aeruginosa resistance by country and antibiotic

Treatment of Drug Resistant TB - Questions

Number of ventilator-associated pneumonia (VAP) patients with newly isolated micro-organisms from endotracheal aspirates after initiation of antibiotic.

Pulmonary arterial hypertension specific medication use at enrolment among previously diagnosed patients. 184 (7%) of patients were not on a prostaglandin,

Cumulative survival estimates for the subgroup of 127 patients with ventilator-associated pneumonia caused by nonfermentative Gram-negative bacilli according.

DR SAUMU WAYUWA KPA ANNUAL SCIENTIFIC CONFERENCE 2019

Impact of dose adjustment in case of adverse drug reaction (ADR; includes dose interruption and/or reduction). a) No dose adjustment and b) dose adjustment.

Survival of idiopathic pulmonary arterial hypertension (IPAH) patients in World Health Organization functional class (FC) at baseline IV is extremely poor.

Diversity of resistant and susceptible isolates.

Figure 4. Clinical course of patients with disseminated MDR-tuberculosis. MTB, Mycobacterium tuberculosis ; B-MRI, brain MRI; B-CT, brain CT; TB, tuberculosis;

Synchronization of a basic diagnostic algorithm (linked diagnostic tests) with different levels of diagnostic services. Synchronization of a basic diagnostic.

Effect of pulmonary arterial hypertension-specific treatment on systemic inflammation. a) Kaplan–Meyer survival curves for patients normalising their C-reactive.

High-resolution computed tomography from a patient with anti-Jo1 positive polymyositis showing basilar predominate reticulation and ground-glass opacity.

Reduction in mean pulmonary vascular resistance (PVR) in 37 subjects following acute sildenafil administration to ongoing bosentan therapy in the COMPASS-1.

Fig. 1. Antituberculosis drug resistance rate (%) and pattern in sanatoria of North Korea: (A) patients (n = 489) in all sanatoria analyzed in this study,

Basic diagnostic algorithm to link the molecular line probe assay with solid culture- and liquid culture-based growth detection and susceptibility testing.

Calcium and vitamin D metabolism.

Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.

Presentation transcript:

STREAM (Evaluation of a Standardised Treatment Regimen of Anti-tuberculosis Drugs for Patients with Multidrug-resistant Tuberculosis) treatment regimens. STREAM (Evaluation of a Standardised Treatment Regimen of Anti-tuberculosis Drugs for Patients with Multidrug-resistant Tuberculosis) treatment regimens. WHO: World Health Organization; MDR-TB: multidrug-resistant tuberculosis; KM: kanamycin; INH: isoniazid; PTO: prothionamide; MFX: moxifloxacin; CFZ: clofazimine; EMB: ethambutol; PZA: pyrazinamide; BDQ: bedaquiline; LFX: levofloxacin. Riya Moodley, and Thomas R. Godec Eur Respir Rev 2016;25:29-35 ©2016 by European Respiratory Society